NeuroSense Therapeutics Ltd. (NRSN) - Dilution Analysis

20-F filing | 32.6M shares outstanding

F-3 filing: NeuroSense Therapeutics Ltd. may offer and sell up to $150,000,000 in the aggregate of ordinary shares, warrants to purchase ordinary shares and/or debt securities, debt securities (including convertible debt securities), subscription rights and/or units consisting of two or more of these classes or series of securities.

F-3 filing: This F-3 filing relates to the resale of 333,334 ordinary shares of NeuroSense Therapeutics Ltd. by a selling shareholder.

POS AM filing: This POS AM filing relates to the resale of up to 9,600,303 ordinary shares by YA under a purchase agreement, where YA has committed to purchase up to $30.0 million of shares at the company's direction, with the proceeds to be used for continued development of pipeline products, new programs, business development, and general corporate purposes.

POS AM filing: This POS AM filing relates to the offering of ordinary shares, PA Shares, and ordinary warrants by selling shareholders.

POS AM filing: This prospectus covers the resale of up to 9,775,303 ordinary shares that we have reserved for issuance and sale to YA under the Purchase Agreement from time to time during the Commitment Period.

POS AM filing: This POS AM filing relates to an offering of Ordinary Shares, Ordinary Warrants, and PA Shares by selling shareholders, with the company potentially receiving proceeds only if the Ordinary Warrants are exercised for cash.

20-F filing | 23.2M shares outstanding

F-3 filing: This F-3 filing outlines the offering of ordinary shares and warrants by selling shareholders. The company will not receive any proceeds from the sale of shares unless the warrants are exercised for cash.

F-3 filing: This F-3 filing relates to the offering of shares, warrants and warrant shares by selling shareholders for resale. The company will not receive any proceeds from such sales unless the warrants are exercised for cash.

F-1 filing: This F-1 filing registers an offering of ordinary shares, including commitment shares and advance shares potentially sold under a purchase agreement, with the company potentially receiving up to $30 million in gross proceeds for pipeline development, new programs, business development, and general corporate purposes. The filing also details risk factors associated with investing in the company's securities.

POS AM filing: This POS AM filing includes information on the offering of ordinary shares and warrants by selling shareholders, with the company not receiving proceeds from the sales except when the warrants are exercised for cash, which would then be used for general corporate purposes and working capital.

F-1 filing: This F-1 filing includes the offering of ordinary shares and warrants by selling shareholders. The company will not receive proceeds from the sale of shares, PA Shares and Ordinary Warrants offered by the selling shareholders. However, to the extent the Ordinary Warrants are exercised for cash, if at all, the company will receive the exercise price of the Ordinary Warrants, resulting in gross proceeds of approximately $4.5 million if all warrants are exercised.

POS AM filing: This prospectus relates to the issuance of up to 1,755,000 of our ordinary shares issuable upon the exercise of warrants, including warrants issued as part of an initial public offering and warrants issued to the underwriters of our initial public offering.

POS AM filing: This POS AM filing relates to the offering of ordinary shares and warrants by a selling shareholder, with the company not receiving proceeds from the sale of shares but potentially receiving proceeds if the warrants are exercised.

20-F filing | 15.4M shares outstanding

POS AM filing: This prospectus relates to the issuance of up to (i) 1,655,000 of our ordinary shares, no par value per share (the "ordinary shares") issuable upon the exercise of warrants that were issued as part of an initial public offering (the "Public Warrants"), at an exercise price of $6.00 per ordinary share and (ii) 100,000 ordinary shares issuable upon the exercise of warrants that were issued to the underwriters of our initial public offering at an exercise price of $7.50 per ordinary share (the "Underwriter Warrants").

POS AM filing: This prospectus relates to the issuance of up to 1,755,000 of our ordinary shares issuable upon the exercise of warrants.

F-1 filing: This F-1 filing outlines an offering of ordinary shares and warrants, including shares issuable upon exercise of warrants, by both the company and a selling shareholder. It details the potential use of proceeds, risk factors, and information regarding the company's foreign private issuer status.

20-F filing | 11.8M shares outstanding

F-3 filing: NEUROSENSE THERAPEUTICS LTD. may offer and sell to the public from time to time in one or more series or issuances up to $100,000,000 in the aggregate of ordinary shares, warrants to purchase ordinary shares and/or debt securities, debt securities (including convertible debt securities), subscription rights and/or units consisting of two or more of these classes or series of securities.

20-F filing | 10.9M shares outstanding